Our Strategic Collaboration

Our collaboration with Weill Cornell Medicine provides LEXEO Therapeutics with access to some of the most advanced translational science in the gene therapy field and a GMP-grade early clinical vector manufacturing capability.  Weill Cornell Medicine continues to conduct IND-enabling preclinical research of investigational gene therapies while synergistically LEXEO is a company focused on clinical development, regulatory strategy, commercial scale manufacturing and global commercialization activities.

Our Investors